The MEA peptide therapeutics CDMO market size was valued at USD 150.00 million in 2025 and is projected to be worth around USD 509.19 million by 2035, expanding at a CAGR of 13% from 2026 to 2035. Growing due to expanding pharmaceutical manufacturing capabilities and rising focus on innovative drug production.

MEA Peptide Therapeutics CDMO Market Statical Scope

The Middle East and Africa therapeutics CDMO market is steadily growing as a result of improved healthcare infrastructure and increased investments in pharmaceutical manufacturing capabilities; governments throughout the region are promoting local drug production to strengthen healthcare security and lessen reliance on imports; growing partnerships between regional manufacturers and multinational pharmaceutical companies are also supporting technology transfer and production expansion; and growing demand for affordable therapeutics and contract manufacturing services is creating new growth opportunities in the market. To lessen reliance on imports and improve healthcare security, governments throughout the area are promoting domestic medicine manufacturing. Technology transfer and production expansion are also being supported by growing collaborations between local producers and multinational pharmaceutical corporations. Additionally, the industry is seeing new development prospects due to the increasing need for reasonably priced medications and contract manufacturing services.

Increased investments in local pharmaceutical manufacturing and better healthcare infrastructure are driving the Middle East and Africa's therapeutics CDMO market. Partnerships with foreign pharmaceutical companies are facilitating technology transfer and enhancing manufacturing capabilities throughout the region, while rising demand for reasonably priced medications and expanding healthcare access are stimulating regional drug production activities. Growing access to healthcare and rising demand for reasonably priced medications are driving regional drug production. Additionally, collaborations with foreign pharmaceutical firms are facilitating technology transfer and enhancing regional manufacturing capacities.

MEA Peptide Therapeutics CDMO Market Share, By Synthesis Method, 2025 (%)

• Solid-Phase Peptide Synthesis (SPPS): Solid-phase peptide synthesis (SPPS) segment dominated the market in 2025 with a market share of 34% driven by increasing demand for efficient peptide manufacturing technologies and rising adoption in therapeutic applications.
• Liquid-Phase Peptide Synthesis (LPPS): Liquid-phase peptide synthesis (LPPS) segment was the fastest growing in the market with a share of 12% driven by increasing focus on economical peptide production and improving industrial manufacturing processes.

MEA Peptide Therapeutics CDMO Market Share, By Service Type, 2025 (%)

• API development & manufacturing: API development & manufacturing segment dominated the market in 2025 with a market share of 25% driven by growing pharmaceutical outsourcing activities and increasing peptide therapeutic production demand.
• Process development & optimization: Process development & optimization segment was the fastest growing in the market with a share of 11%, driven by a growing emphasis on improving production quality and the growing use of advanced manufacturing workflows.

MEA Peptide Therapeutics CDMO Market Share, By Peptide Type, 2025 (%)

• Generic peptide: Generic peptide segment was the fastest growing in the market with a share of 18%, driven by the expanding capacity to produce generic peptide and the growing demand for reasonably priced healthcare solutions.
• Innovative/Novel Peptides: Innovative/Novel peptides segment dominated the market in 2025 with a market share of 24% driven by increasing investments in advanced therapeutics and rising demand for targeted peptide-based treatments.

MEA Peptide Therapeutics CDMO Market Share, By Application Area, 2025 (%)

• Oncology & Cancer Treatment: Oncology & cancer treatment segment dominated the market in 2025 with a market share of 24% driven by increasing cancer prevalence and rising focus on targeted oncology therapies.
• Diabetes & Metabolic Disorders: Diabetes & metabolic disorders segment was the fastest growing in the market with a share of 18% driven by increasing diabetic population and rising adoption of peptide therapeutics for chronic disease management.

MEA Peptide Therapeutics CDMO Market Share, By Scale of Operation, 2025 (%)

• Research & Development Scale: Research & development scale segment dominated the market in 2025 with a market share of 22% driven by increasing investments in peptide drug discovery and growing research collaborations.
• Clinical Trial Manufacturing: Clinical trials manufacturing segment was the fastest growing in the market with a share of 20% driven by increasing clinical development activities and expanding pharmaceutical outsourcing trends.

MEA Peptide Therapeutics CDMO Market Share, By End User Type, 2025 (%)

• Large Pharmaceutical Companies: Large pharmaceutical companies segment dominated the market in 2025 with a market share of 28% driven by increasing peptide drug production activities and strong outsourcing partnerships with CDMOs
• Biotechnology Companies: The Biotechnology companies segment was the fastest growing in the market, with a share of 24%, driven by increasing biotech investments and rising innovation in peptide therapeutics development.

Competitive Landscape

The Middle East & Africa therapeutics CDMO market is gradually becoming competitive with increasing investments in pharmaceutical manufacturing and regional healthcare development. Companies are focusing on partnerships with international pharmaceutical firms to improve manufacturing technologies and product quality standards. Expansion of local drug production facilities and government support for domestic pharmaceutical industries are also supporting competitive growth. Major companies associated with the market include SPIMACO, Julphar, Aspen Pharmacare, Hikma Pharmaceuticals, Jamjoom Pharma, and Adcock Ingram.

Segments Covered in the Report

By Synthesis Method

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid/Mixed-Phase Synthesis
• Recombinant Peptide Production
• Chemical Synthesis Methods
• Enzymatic Synthesis Approaches
• Fragment Condensation Techniques
• Convergent Synthesis Strategies

By Service Type

• API Development & Manufacturing
• Process Development & Optimization
• Analytical Method Development & Validation
• Regulatory Affairs & CMC Support
• Formulation Development
• Fill-Finish & Packaging Services
• Quality Control & Assurance
• Clinical Trial Material Manufacturing
• Commercial Manufacturing
• Technology Transfer Services

By Peptide Type

• Generic Peptides
• Innovative/Novel Peptides
• Modified Peptides (PEGylated, Lipidated)
• Cyclic Peptides
• Stapled Peptides
• Peptide-Drug Conjugates (PDCs)
• Antimicrobial Peptides
• Hormonal Peptides
• Therapeutic Proteins & Peptides
• Cosmetic & Nutraceutical Peptides

By Application Area

• Oncology & Cancer Treatment
• Diabetes & Metabolic Disorders
• Cardiovascular Diseases
• Central Nervous System Disorders
• Infectious Diseases
• Autoimmune & Inflammatory Conditions
• Hormonal Therapies
• Pain Management
• Dermatology & Cosmetics
• Gastrointestinal Disorders

By Scale of Operation

• Research & Development Scale
• Clinical Trial Manufacturing
• Pilot Scale Production
• Commercial Scale Manufacturing
• Large-Scale Industrial Production
• Custom Small Batch Production

By End-User Type

• Large Pharmaceutical Companies
• Biotechnology Companies
• Academic & Research Institutions
• Government Research Organizations
• Clinical Research Organizations (CROs)
• Specialty Pharmaceutical Companies
• Generic Drug Manufacturers
• Cosmetic & Nutraceutical Companies